Factors associated with 2009 monovalent H1N1 vaccine coverage: A cross sectional study of 1308 patients with psoriasis in France
Factors associated with 2009 monovalent H1N1 vaccine coverage: A cross sectional study of 1308 patients with psoriasis in France
复制标题
DOI：
10.1016/j.vaccine.2012.07.014
复制
发表时间：
2012-08-24
期刊：
影响因子：
5.5
通讯作者：
Bachelez, Herve
中科院分区：
文献类型：
--
作者：
Sbidian, Emilie;Tubach, Florence;Bachelez, Herve
背景：免疫介导的炎症性疾病如银屑病患者感染的风险增加。关于疫苗接种的具体建议是可用的，但是慢性炎症性疾病患者的疫苗接种覆盖率受到的关注有限，并且没有关于银屑病患者的研究。目的：评估2009年单价H1N1疫苗接种的覆盖率，并确定银屑病患者中与疫苗接种相关的因素。法国银屑病患者协会的患者成员被发送了一份自我管理的匿名问卷。它包括社会人口学数据、银屑病病史、季节性和疫苗接种状况。与A/H1N1流感疫苗接种相关的因素进行了确定和调整的比值比（ORa）和患病率比（PRa）估计其95%的置信区间（95%CI）使用logistic回归models.Results：1308银屑病患者的平均年龄为58.2岁，完成了2010年9月至12月之间的研究。共有240名（19%）患者接种了2009年单价H1N1疫苗。75名接受生物制剂治疗的患者中有25名（33%）接种了疫苗。既往季节性流感（ORa（PRa）= 10.2（6.6）[6.1（4.1）-16.9（10.7）1），肺炎球菌（ORa（PRa）= 2.0（1.6）[1.2（1.1）-3.3（2.3）1）和B型肝炎（ORa（PRa）= 2.2（1.7）[1.4（1.1）-3.5（2.5）]）接种疫苗与接种甲型H1N1流感疫苗独立相关。这是评估2009年单价H1N1疫苗在银屑病患者中覆盖率的最大规模研究，银屑病是一种高度流行的慢性炎症性疾病。这一疫苗接种覆盖率是法国普通人群的两倍多，但对于接受免疫抑制剂的患者来说仍然很低。具体建议、免费疫苗和大规模全国运动的影响有限，因此需要在未来发生流行病时采取替代战略。(C)2012爱思唯尔有限公司保留所有权利。
Background: Patients with immune-mediated inflammatory diseases like psoriasis are at increased risk of infection. Specific recommendations are available regarding vaccinations however the vaccination coverage in patients with chronic inflammatory diseases has received limited attention and studies are not available in patients with psoriasis.Objectives: To assess the coverage of 2009 monovalent H1N1 vaccination and to identify factors associated with vaccination among patients with psoriasis.Methods: Patients member of the French psoriasis patients association were sent a self administrated anonymous questionnaire. It consisted in socio-demographic data, history of psoriasis, seasonal and vaccination status. Factors associated with vaccination for A/H1N1 influenza were identified and adjusted odds ratios (ORa) and prevalence ratios (PRa) were estimated with their 95% confidence intervals (95% CIs) using logistic regression models.Results: 1308 psoriasis patients with a mean age of 58.2 years completed the study between September and December 2010. A total of 240 (19%) patients received the 2009 monovalent H1N1 vaccine. 25 out of 75 patients treated with biologics (33%) received the vaccine. Previous influenza seasonal (ORa (PRa)= 10.2 (6.6) [6.1 (4.1)-16.9 (10.7)1), pneumococcal (ORa (PRa)= 2.0 (1.6) [1.2 (1.1)-3.3 (2.3)1) and hepatitis B (ORa (PRa)= 2.2 (1.7) [1.4 (1.1)-3.5 (2.5)]) vaccinations were independently associated with being vaccinated for influenza A(H1N1).Conclusion: This is the largest study conducted to assess the coverage of 2009 monovalent H1N1 vaccine among patients with psoriasis, a highly prevalent chronic inflammatory disease. This vaccination coverage is more than twice the one in the French general population, but still remained low for patients receiving immunosuppressants. The limited impact of specific recommendations, free vaccines and the massive national campaign warrant alternative strategies in case of future pandemics. (C) 2012 Elsevier Ltd. All rights reserved.